A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer by Yang James C, Haworth Leah, Sherry Richard M, Hwu Patrick, Schwartzentruber Douglas J, Topalian Suzanne L, Steinberg Seth M, Chen Helen X, Rosenberg Steven A in The New England journal of medicine (2003). PubMed

Abstract

Mutations in the tumor-suppressor gene VHL cause oversecretion of vascular endothelial growth factor by clear-cell renal carcinomas. We conducted a clinical trial to evaluate bevacizumab, a neutralizing antibody against vascular endothelial growth factor, in patients with metastatic renal-cell carcinoma.

[ hide abstract ]

Discussed In Paper

Related In Paper

Variant Annotations

None.